Abstract 292P
Background
Cervical cancer is the second most common malignancy among women in poor countries, according to the World Health Organization. According to some writers, cervical cancer is the second- or third-leading cause of mortality for women over 30 in Uzbekistan. Statistics on cervical cancer are hotly debated because not all women visit a doctor. On the pathologist's table, the diagnosis is frequently made.
Methods
During a regular checkup, 92 women between the ages of 25 and 48 were seen at the antenatal clinic of hospital No. 1g. Using liquid cytology and Pap test technologies, a screening cytological examination was performed on all women. According to clinical recommendations, the PAP test classes were interpreted as follows: class 1 — normal; class 2 — inflammatory type; class 3 — dyskaryosis; class 4 — cells suggestive for cancer or carcinoma; and class 5 — malignancy.
Results
50 women had normal cytological screening results from Pap tests, while 36 had inflammatory type outcomes. There was an inadequate type of sample in 6 women. A negative result of cytological screening by liquid cytology was found in 44 women; 36 women had cytograms that were within the normal range; and 10 women had atypical cells of stratified squamous epithelium that were of unknown significance. Additionally, 2 women developed epithelial squamous lesions of low severity. Compared to liquid cytology, which had a sensitivity of 77.0%, the Pap test had a sensitivity of 33.0%. While liquid cytology had a specificity of 72.0%, the Pap test had a higher specificity of 87.0%. Liquid cytology and the predictive value of a positive Pap test were comparable. Compared to the PAP test, the liquid cytology test had a better predictive value for a negative outcome.
Conclusions
The study's findings revealed that both approaches to early cervical cancer diagnosis estimate the incidence of the condition equally. In addition, liquid cytology makes it more probable to produce a positive result in the group of patients who actually have the disease and, to a lesser extent, in those who do not. When employing the liquid cytology method, the prognosis of the likelihood of the disease being absent in patients with a negative result was higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract